1530 Stock Overview An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for 3SBio Historical stock prices Current Share Price HK$6.05 52 Week High HK$7.85 52 Week Low HK$4.91 Beta 0.73 1 Month Change 6.33% 3 Month Change 6.14% 1 Year Change -9.02% 3 Year Change -8.47% 5 Year Change -36.85% Change since IPO -22.93%
Recent News & Updates
First half 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 1H 2023) Oct 02
Investor sentiment improves as stock rises 22% Sep 30
Co-Founder recently bought HK$1.5m worth of stock Aug 28
First half 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 1H 2023) Aug 25
3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024 Aug 12
Upcoming dividend of HK$0.25 per share Jul 15 See more updates
First half 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 1H 2023) Oct 02
Investor sentiment improves as stock rises 22% Sep 30
Co-Founder recently bought HK$1.5m worth of stock Aug 28
First half 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 1H 2023) Aug 25
3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024 Aug 12
Upcoming dividend of HK$0.25 per share Jul 15
3Sbio Inc. Announces Management Changes Apr 23
New minor risk - Dividend sustainability Apr 10 3SBio Inc., Annual General Meeting, Jun 25, 2024
3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 06
Mandi Foam of 3SBio Inc. Approves for Market Launch Jan 09
First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.40 in 1H 2022) Sep 30
First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022) Aug 25
3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023 Aug 12
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer Jul 29
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market Jul 06
Upcoming dividend of HK$0.10 per share at 1.3% yield Jun 20 3SBio Inc., Annual General Meeting, Jun 20, 2023
Full year 2022 earnings released: EPS: CN¥0.78 (vs CN¥0.65 in FY 2021) Apr 30
Full year 2022 earnings released: EPS: CN¥0.78 (vs CN¥0.65 in FY 2021) Mar 22
Now 22% undervalued Jan 30
3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director Jan 04
3Sbio Inc. Announces Executive Changes Dec 31
Investor sentiment improved over the past week Nov 26
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Oct 07
First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021) Oct 04
First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021) Aug 25
3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022 Aug 13
3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021 Jun 23
Upcoming dividend of HK$0.20 per share Jun 20
3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao ) May 12
Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020) May 02
Less than half of directors are independent Apr 27
Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020) Mar 31
3SBio Inc., Annual General Meeting, Jun 22, 2022 Mar 31 3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022
Investor sentiment improved over the past week Mar 21
3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021 Feb 08
First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020) Oct 03
Investor sentiment improved over the past week Sep 01
3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point Aug 31
First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020) Aug 28
Investor sentiment deteriorated over the past week Jul 28
3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point Jul 23
Company Secretary Suet Wing Leung has left the company Jul 20
Independent Non-Executive Director David Parkinson has left the company Jul 06
Investor sentiment improved over the past week Jun 23
Investor sentiment improved over the past week May 31
Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019) May 02
Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019) Mar 31
3SBio Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021 Mar 12
3Sbio Inc. Announces Completion the Enrolment of Subjects for Phase Ii Clinical Study Feb 24
New 90-day high: HK$8.42 Feb 18
3SBio Inc. Provides Update on License Agreement with AstraZeneca and Hongkong Sansheng Feb 06
New 90-day high: HK$7.81 Jan 25
New 90-day low: HK$7.06 Dec 09
3Sbio Inc. Receives Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-212 Nov 25
New 90-day low: HK$7.19 Nov 19
New 90-day low: HK$8.13 Oct 14
First half earnings released Oct 01
New 90-day low: HK$8.22 Sep 25
3SBio Inc. to Report First Half, 2020 Results on Aug 17, 2020 Sep 22
New 90-day low - HK$8.98 Sep 04
First half earnings released Aug 20 Shareholder Returns 1530 HK Biotechs HK Market 7D -1.6% -3.9% -0.5% 1Y -9.0% -5.7% 19.9%
See full shareholder returns
Return vs Market: 1530 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility Is 1530's price volatile compared to industry and market? 1530 volatility 1530 Average Weekly Movement 6.8% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 1530 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1530's weekly volatility (7%) has been stable over the past year.
About the Company 3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium.
Show more 3SBio Inc. Fundamentals Summary How do 3SBio's earnings and revenue compare to its market cap? 1530 fundamental statistics Market cap HK$14.25b Earnings (TTM ) HK$1.77b Revenue (TTM ) HK$8.98b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1530 income statement (TTM ) Revenue CN¥8.42b Cost of Revenue CN¥1.18b Gross Profit CN¥7.24b Other Expenses CN¥5.58b Earnings CN¥1.66b
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) 0.70 Gross Margin 85.94% Net Profit Margin 19.69% Debt/Equity Ratio 24.7%
How did 1530 perform over the long term?
See historical performance and comparison Dividends
4.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 02:58 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources 3SBio Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sharon Shi BOCI Research Ltd. Ruyi Tang BOCI Research Ltd. Difei Yang Capstone Investments
Show 31 more analysts 
